Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?
Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P, Kremens B, Dilloo D, Sykora KW, Schrappe M, Niemeyer C, Von Stackelberg A, Gruhn B, Henze G, Greil J, Niethammer D, Dietz K, Beck JF, Klingebiel T. Bader P, et al. Among authors: dilloo d. J Clin Oncol. 2004 May 1;22(9):1696-705. doi: 10.1200/JCO.2004.05.198. J Clin Oncol. 2004. PMID: 15117992
Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy.
Bader P, Niemeyer C, Willasch A, Kreyenberg H, Strahm B, Kremens B, Gruhn B, Dilloo D, Vormoor J, Lang P, Niethammer D, Klingebiel T, Beck JF. Bader P, et al. Among authors: dilloo d. Br J Haematol. 2005 Mar;128(5):649-58. doi: 10.1111/j.1365-2141.2004.05354.x. Br J Haematol. 2005. PMID: 15725087 Free article. Clinical Trial.
Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective.
Bader P, Kreyenberg H, Hoelle W, Dueckers G, Kremens B, Dilloo D, Sykora KW, Niemeyer C, Reinhardt D, Vormoor J, Gruhn B, Lang P, Greil J, Handgretinger R, Niethammer D, Klingebiel T, Beck JF. Bader P, et al. Among authors: dilloo d. Bone Marrow Transplant. 2004 Apr;33(8):815-21. doi: 10.1038/sj.bmt.1704444. Bone Marrow Transplant. 2004. PMID: 14990984 Clinical Trial.
Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia.
Yoshimi A, Niemeyer CM, Bohmer V, Duffner U, Strahm B, Kreyenberg H, Dilloo D, Zintl F, Claviez A, Wössmann W, Kremens B, Holter W, Niethammer D, Beck JF, Kontny U, Nöllke P, Klingebiel T, Bader P. Yoshimi A, et al. Among authors: dilloo d. Br J Haematol. 2005 May;129(4):542-9. doi: 10.1111/j.1365-2141.2005.05489.x. Br J Haematol. 2005. PMID: 15877738 Free article.
Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.
Woessmann W, Peters C, Lenhard M, Burkhardt B, Sykora KW, Dilloo D, Kremens B, Lang P, Führer M, Kühne T, Parwaresch R, Ebell W, Reiter A. Woessmann W, et al. Among authors: dilloo d. Br J Haematol. 2006 Apr;133(2):176-82. doi: 10.1111/j.1365-2141.2006.06004.x. Br J Haematol. 2006. PMID: 16611309 Free article.
Osteosarcoma after allogeneic bone marrow transplantation. A report of four cases from the Cooperative Osteosarcoma Study Group (COSS).
Bielack SS, Rerin JS, Dickerhoff R, Dilloo D, Kremens B, von Stackelberg A, Vormoor J, Jürgens H; Cooperative German-Austrian-Swiss Osteosarcoma Study Group (COSS). Bielack SS, et al. Among authors: dilloo d. Bone Marrow Transplant. 2003 Mar;31(5):353-9. doi: 10.1038/sj.bmt.1703864. Bone Marrow Transplant. 2003. PMID: 12634726
Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia.
Yoshimi A, Bader P, Matthes-Martin S, Starý J, Sedlacek P, Duffner U, Klingebiel T, Dilloo D, Holter W, Zintl F, Kremens B, Sykora KW, Urban C, Hasle H, Korthof E, Révész T, Fischer A, Nöllke P, Locatelli F, Niemeyer CM; European Working Group of MDS in Childhood (EWOG-MDS). Yoshimi A, et al. Among authors: dilloo d. Leukemia. 2005 Jun;19(6):971-7. doi: 10.1038/sj.leu.2403721. Leukemia. 2005. PMID: 15800672 Clinical Trial.
Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia.
Meissner B, Borkhardt A, Dilloo D, Fuchs D, Friedrich W, Handgretinger R, Peters C, Schrauder A, Schuster FR, Vormoor J, Maecker B, Sykora KW, Zintl F, Welte K, Sauer M. Meissner B, et al. Among authors: dilloo d. Bone Marrow Transplant. 2007 Nov;40(10):945-9. doi: 10.1038/sj.bmt.1705844. Epub 2007 Sep 3. Bone Marrow Transplant. 2007. PMID: 17768387
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR.
Berthold F, Faldum A, Ernst A, Boos J, Dilloo D, Eggert A, Fischer M, Frühwald M, Henze G, Klingebiel T, Kratz C, Kremens B, Krug B, Leuschner I, Schmidt M, Schmidt R, Schumacher-Kuckelkorn R, von Schweinitz D, Schilling FH, Theissen J, Volland R, Hero B, Simon T. Berthold F, et al. Among authors: dilloo d. Ann Oncol. 2020 Mar;31(3):422-429. doi: 10.1016/j.annonc.2019.11.011. Epub 2020 Jan 24. Ann Oncol. 2020. PMID: 32067684 Free article. Clinical Trial.
107 results